Overview

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

Status:
Not yet recruiting
Trial end date:
2027-12-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb